Combination radiotherapy and chemotherapy in murine bladder cancer

Weldon, Thomas E.; Kursh, Elroy D.; Novak, Louis J.; Persky, Lester

doi:10.1016/0090-4295(79)90212-7

Cited by 18 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our literature analysis, we found only two in vitro and four in vivo (preclinical) studies investigating cisplatin and RT in BCa (Table 5). Weldon et al, for the first time, used cisplatin in combination with RT in a murine BCa model and compared different administration schedules and included also two other drugs for comparison [18]. They found that the concomitant administration of cisplatin and RT was toxic, but when cisplatin was used as adjuvant therapy after completion of RT, synergistic effect was produced, but another CT drug cyclophosphamide was more effective in terms of growth delay [18].…”

Section: Cisplatinmentioning

confidence: 99%

“…Weldon et al, for the first time, used cisplatin in combination with RT in a murine BCa model and compared different administration schedules and included also two other drugs for comparison [18]. They found that the concomitant administration of cisplatin and RT was toxic, but when cisplatin was used as adjuvant therapy after completion of RT, synergistic effect was produced, but another CT drug cyclophosphamide was more effective in terms of growth delay [18]. Further, a study by Kyriazis et al observed the most synergistic effect when cisplatin was given on days 3 and 6 post-radiation using human BCa xenograft model (SW-800, not classified cell line) [79].…”

Section: Cisplatinmentioning

confidence: 99%

“…Although RT has been used in bladder cancer (BCa) treatment since the 1950s, there is a relatively low number of experimental studies on the topic of radiosensitisers in BCa compared to other cancer types. The first study identified was in the 1979 [18]. Altogether, we identified 85 studies investigating RT in BCa experimental models published between 1979 and October 2020.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives

Silina

Maksut

Bernard‐Pierrot

et al. 2020

Cancers

View full text Add to dashboard Cite

Bladder cancer is among the top ten most common cancer types in the world. Around 25% of all cases are muscle-invasive bladder cancer, for which the gold standard treatment in the absence of metastasis is the cystectomy. In recent years, trimodality treatment associating maximal transurethral resection and radiotherapy combined with concurrent chemotherapy is increasingly used as an organ-preserving alternative. However, the use of this treatment is still limited by the lack of biomarkers predicting tumour response and by a lack of targeted radiosensitising drugs that can improve the therapeutic index, especially by limiting side effects such as bladder fibrosis. In order to improve the bladder-preserving treatment, experimental studies addressing these main issues ought to be considered (both in vitro and in vivo studies). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews, we conducted a literature search in PubMed on experimental studies investigating how to improve bladder cancer radiotherapy with different radiosensitising agents using a comprehensive search string. We made comments on experimental model selection, experimental design and results, formulating the gaps of knowledge still existing: such as the lack of reliable predictive biomarkers of tumour response to chemoradiation according to the molecular tumour subtype and lack of efficient radiosensitising agents specifically targeting bladder tumour cells. We provided guidance to improve forthcoming studies, such as taking into account molecular characteristics of the preclinical models and highlighted the value of using patient-derived xenografts as well as syngeneic models. Finally, this review could be a useful tool to set up new radiation-based combined treatments with an improved therapeutic index that is needed for bladder preservation.

show abstract

Section: Cisplatinmentioning

confidence: 99%

Section: Cisplatinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives

Silina

Maksut

Bernard‐Pierrot

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

Combined intraarterial chemotherapy and radiotherapy in the treatment of Bladder carcinoma

Mokarim

Uetani

Hayashi

et al. 1997

Cancer

View full text Add to dashboard Cite

show abstract

Unresectable carcinoma of the bladder

Montie

Whitmore

Grabstald

et al. 1983

Cancer

View full text Add to dashboard Cite

The clinical courses of 119 patients with unresectable bladder cancer were analyzed. All patients had a laparotomy with the intent of cystectomy. TN categorization postlaparotomy did not identify variables significantly influencing the natural history of the disease, although previous definitive irradiation or T4aNx–4 categories were associated with especially poor survival. T category correlated more closely with survival than did N category. Supravesical urinary diversion palliated patients with urinary symptoms and/or bilateral ureteral obstruction. Patients without compelling urinary symptoms at the time of laparotomy uncommonly needed diversion later. Pelvic irradiation and systemic chemotherapy available in the interval from 1961 to 1976 had minimal if any demonstrable effect on the time course of the disease.

show abstract

Combination radiotherapy and chemotherapy in murine bladder cancer

Cited by 18 publications

References 15 publications

Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives

Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives

Combined intraarterial chemotherapy and radiotherapy in the treatment of Bladder carcinoma

Unresectable carcinoma of the bladder

Contact Info

Product

Resources

About